Pre-heart failrue
Conditions
Interventions
Henagliflozin group:Participants are randomly assigned into Henagliflozin group (10mg/qd) for 24 weeks
Control group:Participants are randomly assigned into control group for 24 weeks
Sponsors
Guangdong Provincial Yingde People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years with a prior diagnosis of hypertension, diabetes, coronary artery disease, chronic kidney disease, microalbuminuria or macroalbuminuria, obesity, or other risk factors for heart failure; 2. Plasma NT-proBNP levels meeting the age-specific threshold for heart stress: >= 75 pg/mL for individuals = 150 pg/mL for those aged 50–74, and >= 300 pg/mL for those >= 75 years old; 3. No clinical signs or symptoms of heart failure; 4. Signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with Stage C heart failure (presence of typical symptoms or signs); 2. eGFR < 30 mL/min/1.73m^2 or requiring dialysis; 3. Recent (within the past 3 months) acute myocardial infarction, stroke, or unstable angina; 4. Currently using other SGLT2 inhibitors or GLP-1 receptor agonists; 5. Presence of severe liver dysfunction, active infection, or malignancy; 6. History of diabetic ketoacidosis, type 1 diabetes mellitus, or gestational diabetes; 7. Pregnant or breastfeeding women, or those planning pregnancy; 8. Moderate to severe mitral or aortic valve stenosis or regurgitation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| N-terminal pro-B-type netriuretic peptide; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac structure and function on echocardiography; | — |
Countries
China
Contacts
Public ContactAnping Cai
Guangdong Provincial Yingde People's Hospital
Outcome results
None listed